BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38760830)

  • 1. HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?
    Becker AK; Puladi B; Xie K; Cassataro A; Götzl R; Hölzle F; Beier JP; Knüchel-Clarke R; Braunschweig T
    World J Surg Oncol; 2024 May; 22(1):131. PubMed ID: 38760830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical value of fluorescence
    Wang W; Li X; Liu P; Dong Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):228-233. PubMed ID: 37042132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FISH Diagnostic Assessment of
    Gambella A; Bertero L; Rondón-Lagos M; Verdun Di Cantogno L; Rangel N; Pitino C; Ricci AA; Mangherini L; Castellano I; Cassoni P
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674856
    [No Abstract]   [Full Text] [Related]  

  • 5. Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.
    Kimura H; Dobashi Y; Nojima T; Nakamura H; Yamamoto N; Tsuchiya H; Ikeda H; Sawada-Kitamura S; Oyama T; Ooi A
    Int J Clin Exp Pathol; 2013; 6(7):1306-16. PubMed ID: 23826411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
    Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F
    Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of
    Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
    Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
    Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL
    Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor.
    Kashima T; Halai D; Ye H; Hing SN; Delaney D; Pollock R; O'Donnell P; Tirabosco R; Flanagan AM
    Mod Pathol; 2012 Oct; 25(10):1384-96. PubMed ID: 22699518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
    Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
    Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
    Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T
    Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT6 is amplified in a subset of dedifferentiated liposarcoma.
    Doyle LA; Tao D; Mariño-Enríquez A
    Mod Pathol; 2014 Sep; 27(9):1231-7. PubMed ID: 24457460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
    Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
    Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of Fédération Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases.
    Jour G; Gullet A; Liu M; Hoch BL
    Mod Pathol; 2015 Jan; 28(1):37-47. PubMed ID: 25059573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons learnt from MDM2 fluorescence in-situ hybridisation analysis of 439 mature lipomatous lesions with an emphasis on atypical lipomatous tumour/well-differentiated liposarcoma lacking cytological atypia.
    Vargas AC; Joy C; Cheah AL; Jones M; Bonar F; Brookwell R; Garrone B; Talbot J; Harraway J; Gill AJ; Maclean FM
    Histopathology; 2022 Jan; 80(2):369-380. PubMed ID: 34523152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.
    Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ
    Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms.
    Weaver J; Downs-Kelly E; Goldblum JR; Turner S; Kulkarni S; Tubbs RR; Rubin BP; Skacel M
    Mod Pathol; 2008 Aug; 21(8):943-9. PubMed ID: 18500263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
    Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
    Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.
    Weaver J; Goldblum JR; Turner S; Tubbs RR; Wang WL; Lazar AJ; Rubin BP
    Mod Pathol; 2009 Jan; 22(1):66-70. PubMed ID: 18836421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.